EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan

Kazuki Tomura, Hiroyuki Sakamaki, Shuichi Nawata, Hiroo Ishida, Katsumi Tanaka, Mari Kogo

International Journal of Clinical Pharmacy · 2025

DOI: 10.1007/s11096-024-01826-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Kazuki Tomura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmaceutics, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k-tomura@cmed.showa…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pembrolizumab monotherapy significantly extends progression-free and overall survival compared to platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC), but also has a significant impact on medical costs. AIM: To clarify the health economic evidence for selecting the first-line treatment for patients with stage IV advanced NSCLC with a programmed cell death ligand 1 tumor proportion score of 50% or greater in Japan, we assessed the cost-effectiveness of pembrolizumab monotherapy compared with that of platinum-based chemotherapy. METHOD: Using a Markov model, the study simulated three health states for patients, based on clinical data and utility values from KEYNOTE-024. Transition probabilities were estimated exponentially. Direct medical costs were calculated according to the 2022 National Health Insurance Medical Fee Points and Drug Price Standards. The outcomes measured included life years, quality-adjusted life years, and incremental cost-effectiveness ratio, with sensitivity analysis performed to evaluate the effect of uncertainties. RESULTS: Pembrolizumab led to an additional 1.58 life years and 1.23 quality-adjusted life years at an additional cost of 7,009,888 Japanese yen (48,448 U.S. dollars [USD]), resulting in incremental cost-effectiveness ratio of 4,436,638 Japanese yen (30,663 USD) per life year and 5,699,096 Japanese yen (39,388 USD) per quality-adjusted life year. Pembrolizumab was deemed cost-effective under a threshold of 7.5 million Japanese yen (51,835 USD) per quality-adjusted life year. CONCLUSION: Pembrolizumab monotherapy is a cost-effective option for the first-line treatment of advanced NSCLC with high programmed cell death ligand 1 expression in Japan, providing valuable health economic evidence for treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenAntineoplastic Agents, ImmunologicalHumansCost-Benefit AnalysisJapanQuality-Adjusted Life YearsMarkov ChainsCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cost-benefit analysisLung neoplasmsMarkov chainsPembrolizumabQuality-adjusted life years

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedB7-H1 AntigenAntineoplastic Agents, ImmunologicalCD274 protein, human

Autor:innen und Institutionen

  • Department of Hospital Pharmaceutics, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k-tomura@cmed.showa-u.ac.jp.
  • Graduate School of Health Innovation, Kanagawa University of Human Services, Research Gate Building TONOMACHI 2 3-25-10 Tonomachi, Kawasaki-ku, Kawasaki-shi, 210-0821, Kanagawa, Japan.
  • Department of Hospital Pharmaceutics, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Division of Medical Oncology, Department of Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuduki-ku, Yokohama, 224-8503, Kanagawa, Japan.
  • Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.

Zitieren

APA

Tomura, K., Sakamaki, H., Nawata, S., Ishida, H., Tanaka, K., & Kogo, M. (2025). Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01826-7

Vancouver

Tomura K, Sakamaki H, Nawata S, Ishida H, Tanaka K, Kogo M. Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-024-01826-7

BibTeX
@article{Tomura2025,
  author = {Tomura, Kazuki and Sakamaki, Hiroyuki and Nawata, Shuichi and Ishida, Hiroo and Tanaka, Katsumi and Kogo, Mari},
  title = {Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan},
  journal = {International Journal of Clinical Pharmacy},
  year = {2025},
  doi = {10.1007/s11096-024-01826-7}
}
Kostenlos starten →